Next Article in Journal
Factors Influencing the Clinical Presentation of Breakthrough Pain in Cancer Patients
Previous Article in Journal
The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia
Open AccessReview

Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics

1
INSERM U1037, CRCT, Université Paul Sabatier, 31037 Toulouse, France
2
Laboratoire d’Excellence TouCAN, 31037 Toulouse, France
3
Pathology Department, IUCT-O, Hôpitaux de Toulouse, 31037 Toulouse, France
*
Author to whom correspondence should be addressed.
Cancers 2018, 10(6), 174; https://doi.org/10.3390/cancers10060174
Received: 9 May 2018 / Revised: 29 May 2018 / Accepted: 30 May 2018 / Published: 1 June 2018
For patients with metastatic pancreatic cancer that are not eligible for surgery, signal-targeted therapies have so far failed to significantly improve survival. These therapeutic options have been tested in phase II/III clinical trials mostly in combination with the reference treatment gemcitabine. Innovative therapies aim to annihilate oncogenic dependency, or to normalize the tumoural stroma to allow immune cells to function and/or re-vascularisation to occur. Large scale transcriptomic and genomic analysis revealed that pancreatic cancers display great heterogeneity but failed to clearly delineate specific oncogene dependency, besides oncogenic Kras. Beyond these approaches, proteomics appears to be an appropriate approach to classify signal dependency and to identify specific alterations at the targetable level. However, due to difficulties in sampling, proteomic data for this pathology are scarce. In this review, we will discuss the current state of clinical trials for targeted therapies against pancreatic cancer. We will then highlight the most recent proteomic data for pancreatic tumours and their metastasis, which could help to identify major oncogenic signalling dependencies, as well as provide future leads to explain why pancreatic tumours are intrinsically resistant to signal-targeted therapies. We will finally discuss how studies on phosphatidylinositol-3-kinase (PI3K) signalling, as the paradigmatic pro-tumoural signal downstream of oncogenic Kras in pancreatic cancer, would benefit from exploratory proteomics to increase the efficiency of targeted therapies. View Full-Text
Keywords: pancreatic cancer; proteomics; PI3K pathway; precision medicine; predictor of therapeutic response; integrated biology; proteo-genomics pancreatic cancer; proteomics; PI3K pathway; precision medicine; predictor of therapeutic response; integrated biology; proteo-genomics
Show Figures

Graphical abstract

MDPI and ACS Style

Cintas, C.; Douché, T.; Therville, N.; Arcucci, S.; Ramos-Delgado, F.; Basset, C.; Thibault, B.; Guillermet-Guibert, J. Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics. Cancers 2018, 10, 174.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop